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OBJECTIVE — A1C6.5%hasbeenrecentlyproposedasthedeﬁningcriterionfordiabetes.
However, performance characteristics of this deﬁnition have not been described.
RESEARCH DESIGN AND METHODS — In the Insulin Resistance Atherosclerosis
Study, we compared new to previous deﬁnitions of diabetes: 1999 World Health Organization
(DM1999WHO) and 2003 American Diabetes Association based on fasting glucose alone
(DMFPG126).
RESULTS — ParticipantswithA1C6.5%,DM1999WHO,andDMFPG126were44(5.2%),132
(15.4%), and 61 (7.1%), respectively. In individuals with DM1999WHO, mean, median, and
interquartile range of A1C were 6.3, 5.9, and 5.5–6.6%, respectively; in individuals with DM-
FPG126, mean, median, and interquartile range of A1C were 7.0, 6.6, and 6.0–7.1%.
CONCLUSIONS —A 1 C6.5% identiﬁes fewer individuals than DM1999WHO or DM-
FPG126. Studies are needed to determine that A1C 6.5% compromises neither blood pressure
and lipid management in early diabetes nor the implementation of lifestyle interventions for
diabetes prevention.
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A
nexpertcommitteerecentlyrecom-
mended using A1C as the preferred
marker for diagnosing diabetes
(6.5%) and detecting individuals at the
highestriskfordevelopingdiabetes(6.0–
6.4%) (1). Early deﬁnition attempts were
basedonaperceivedbimodalglucosedis-
tribution in some populations (2) and
later on the relationship between glucose
levelsandthepresenceoflong-termcom-
plications, particularly retinopathy (3).
A1C is now recommended, because A1C
correlates well with retinopathy (4) and
has superior technical attributes (less bi-
ologicalvariabilityandmoreconvenience
by requiring no fasting or timed samples)
(1). However, clinical consequences of
A1C testing are not known.
In this study, we compared perfor-
mance characteristics of the new deﬁni-
tion relative to the 1999 World Health
Organization (WHO) (DM1999WHO) (5)
and 2003 American Diabetes Association
(ADA) (DMFPG126) (6) deﬁnitions in the
Insulin Resistance Atherosclerosis Study
(IRAS) (5).
RESEARCH DESIGN AND
METHODS— The design and meth-
ods of the IRAS have been previously de-
scribed (7). The IRAS protocol was
approved by local institutional review
committees,andallparticipantsprovided
written informed consent.
We used follow-up data (n  855),
because A1C was not measured at base-
line. DMFPG126 was deﬁned as fasting
plasma glucose concentration 126
mg/dl (6) and DM1999WHO as fasting
plasma glucose concentration 126
mg/dl and/or 2-h plasma glucose concen-
tration 200 mg/dl (5). Individuals
treated with antidiabetic medications
were excluded. Indication for treatment
with antihypertensive and LDL-lowering
medications was examined using the
Seventh Report of the Joint Committee
on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure
(JNC-7) and the National Cholesterol
Education Program–Adult Treatment
Panel III (NCEP-ATPIII) guidelines,
respectively.
Logisticregressionmodelwasusedto
study the diagnostic performance of A1C
using receiver operating characteristic
(ROC) curves (SAS statistical software,
version 9.1; SAS, Cary, NC).
RESULTS— The number of partici-
pants with A1C 6.0, 6.0–6.4, and
6.5% was 766 (89.5%), 45 (5.3%), and
44 (5.2%), respectively. A1C 6.0–6.4%
and 6.5% categories had comparable
insulin sensitivity index (0.45  0.10 vs.
0.46  0.76  10
4 min
1   U
1  
ml
1, P  0.994) and metabolic syn-
drome prevalence (71.3% [56.0–82.9]
vs. 80.5% [66.1–89.7], P  0.519) (see
supplementary Table 1 in the online appen-
dix, available at http://care.diabetesjournals.
org/cgi/content/full/dc09-1357/DC1). How-
ever, acute insulin response was higher in
the A1C 6.0–6.4% category (51.4  6.3
vs. 27.2  3.4 U/ml, P  0.001).
Therewere132(15.4%)individuals
with DM1999WHO and 61 (7.1%) with
DMFPG126. In individuals with
DM1999WHO, mean, median, and inter-
quartilerangeofA1Clevelswere6.3,5.9,
and 5.5–6.6%, respectively; in individu-
als with DMFPG126, mean, median, and
interquartilerangeofA1Clevelswere7.0,
6.6, and 6.0–7.1%. The area under the
ROC curve of A1C for identifying partic-
ipants with DM1999WHO and DMFPG126
was 0.843 and 0.931, respectively (Fig.
1).Becauseofthelowsensitivityandhigh
speciﬁcity, A1C 6.5% was a strong in-
dicator of the presence of DM1999WHO
and DMFPG126; however, absence of A1C
6.5% could exclude neither. To a cer-
tain degree, results were similar for the
6.0% A1C threshold.
Among the 92 individuals with
DM1999WHO and A1C 6.5, 75.8, and
82.6% met the criteria for antihyperten-
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treatment (LDL cholesterol 100 mg/dl),
respectively. Because these individuals
were considered nondiabetic by the new
deﬁnition, only 56.0 and 59.1% fulﬁlled
the requirements for treatment by JNC-7
(140/90 mmHg) and NCEP-ATPIII
(based on global risk score) guidelines,
respectively; consequently, 19.8 and
23.5% could potentially miss treatment.
CONCLUSIONS — The number of
individuals identiﬁed by A1C 6.5% is
one-thirdthenumberofindividualsiden-
tiﬁed with the 1999 WHO criteria and
70% the number of individuals identiﬁed
with the 2003 ADA criteria. Individuals
with A1C 6.0–6.4% differ little from
thosewithA1C6.5%intermsofinsulin
resistance and metabolic syndrome, but
have less -cell dysfunction.
Thequestionwhetherthenewdeﬁni-
tion of diabetes (A1C 6.5%) improves
previous attempts falls outside the scope
of this study. Outcome data are needed.
A1C correlates well with retinopathy (4),
but 2-h glucose concentration better pre-
dicts mortality and/or cardiovascular dis-
ease than A1C and fasting glucose
concentration in most studies (8–11) but
not all (12). Our results indicate that A1C
6.5% is insensitive; therefore, this
threshold could jeopardize treatment
beneﬁts of blood pressure and lipids in
early diabetes.
Insulinresistanceis,forthemostpart,
fully developed, and -cell function is
largely compromised in individuals with
impaired glucose tolerance (13). Because
more than half of the individuals with
DM1999WHO have A1C levels 6.0%, this
A1C threshold has the potential of deem-
phasizing the implementation of lifestyle
interventions with proven efﬁcacy for
preventing diabetes (14).
Asigniﬁcantlimitationofourstudyis
theuseofsingledeterminationsofplasma
glucose levels to diagnose diabetes. Con-
cordance for obtaining fasting glucose
concentration 126 mg/dl (or 2-h glu-
cose concentration 140 mg/dl) in two
different days is 70% (15). However, im-
precision in measurement cannot explain
much of the disparity between the new
and 1999 WHO deﬁnitions.
In summary, the new deﬁnition iden-
tiﬁes fewer individuals than the 1999
WHO deﬁnition. Studies are needed to
demonstrate that the 6.5 and 6.0% A1C
cut-points compromise neither the man-
agement of blood pressure and lipids in
early diabetes nor the implementation of
lifestyle interventions to delay the disease
process. New and old deﬁnitions should
be tested in studies with outcome data.
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